Table 1

Literature-based estimates of relative increase in events related to the non-receipt of various components of acute coronary syndrome care

EventsRelative riskUpper estimateLower estimateReference
Presentation
No delay123
Delay 3–6 h1.211.45123
Delay 6>h1.471.761.1823
Reperfusion
PPCI optimal123
PPCI delay1.241.49123
Lysis optimal1.11.32123
Lysis delay1.281.521.0223
None1.471.761.1823
Invasive management
Timely invasive1
Delayed invasive1.101.210.7521
None1.222.000.7524
Pharmacotherapy
GP IIb/IIIa inhibition1.091.18125
ASA1.321.431.2226
Statin1.451.561.3527
Clopidogrel1.411.791.1128
ACE inhibition or ARB1.191.371.0329
β Blocker1.301.451.1830
  • Risk associated with omission calculated as the inverse of the clinical trial based estimate or relative benefit.

  • ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme; ASA, acetylsalicylic acid (aspirin); GP, glycoprotein; PPCI, primary percutaneous coronary intervention.